GlassScriptPhysician profile
Rajendra R Kattar
NPI 1659373942
$37,338.04
in general payments reported to CMS, 2019-2025
30 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,464 · 2020: $12K · 2021: $13K · 2022: $1,237 · 2023: $2,429 · 2024: $1,690 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Travel and Lodging: $498 · Consulting Fee: $201 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Travel and Lodging | $497.62 |
| Consulting Fee | $201.07 |
| Education | $131.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,153.75 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Pfizer INC. | $8,875.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,952.78 | 2021-2025 | |
| Abbott Laboratories | $905.45 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $829.88 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $736.19 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $577.43 | 2019-2025 | |
| Amarin Pharma, INC. | $321.67 | 2019-2022 | |
| Amgen INC. | $310.94 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $308.24 | 2021-2025 | Verquvo |
| Abiomed | $303.71 | 2024 | Impella |
| Janssen Scientific Affairs, LLC | $243.21 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.80 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $219.89 | 2023-2025 | Watchman Flx, Farapulse, Watchman |
| Jenavalve Technology, INC. | $201.07 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.88 | 2019-2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $198.00 | 2024 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $180.55 | 2019-2024 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $137.35 | 2023-2024 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $67.91 | 2023 | |
| Scpharmaceuticals INC. | $53.76 | 2023-2025 | |
| Esperion Therapeutics, INC. | $51.30 | 2020-2021 | |
| Daiichi Sankyo INC. | $47.59 | 2019-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $44.84 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $44.30 | 2019 | |
| Inari Medical, INC. | $40.82 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals International, Plc | $35.62 | 2024 | Arcalyst |
| Atricure, INC. | $32.79 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $26.33 | 2023 | Arcalyst |
| Heartflow, INC. | $16.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Kattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.